Menu
← Oncology Approval Tracker
FDA DECISION ·
Frindovyx
cyclophosphamide · Avyxa Holdings
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
An IV cyclophosphamide presentation for labeled malignancies including selected lymphomas, leukemias, multiple myeloma, mycosis fungoides, neuroblastoma and specified solid tumors.
LAMPGEN ANALYSIS
Why it matters
This separate NDA adds an IV presentation of an established alkylating drug.
What research teams should watch
Record the exact presentation used in the protocol and match preparation to the product-specific label.
PRIMARY RECORDS